A Comparison of the Effects of Losartan and Ramipril on Blood Pressure, Renal Volume and Progression in Polycystic Kidney Disease: A 5-Year Follow-up

Overview

Journal Hippokratia

Specialty General Medicine

Date 2013 Aug 13

PMID 23935270

Citations 2

Authors

S Ulusoy

G Ozkan

P Kosucu

K Kaynar

I Eyuboglu

Affiliations

Soon will be listed here.

Abstract

Background: The major cause of hereditary renal failure is autosomal dominant polycystic kidney disease (ADPKD). Many factors affect renal progression in these patients. Among these, hypertension and an increase in renal volume are interrelated in terms of their effects on renal progression. We aimed to investigate the effects of losartan and ramipril on renal volume and progression in patients with ADPKD.

Materials And Methods: Data from 18 hypertensive patients with ADPKD were evaluated. Eleven of the 18 hypertensive patients were on losartan and 7 on ramipril treatment. Demographic parameters, use of antihypertensives and other medications, the course of blood pressure (BP), biochemical parameters, creatinine clearance (CrCL), findings at computed tomography and renal volume were recorded at baseline and at 1 and 5 years.

Results: Target BP values were maintained over 5 years. The annual decrease in CrCL was 1.33 mL/min in the losartan group compared with 6.59 mL/min in the ramipril group. There was no significant difference between the groups in terms of annual decrease in CrCL. Annual increase in renal volume was 252.04 cm³ in the losartan group and 167.36 cm³ in the ramipril group. There was no significant difference between the groups in terms of the increase in renal volumes at 1 and 5 years.

Conclusion: Our study demonstrated that losartan and ramipril provided effective BP control. In addition, the results of our study demonstrated that despite the increase in renal volume, losartan and ramipril may have regressed renal progression via other factors.

Citing Articles

Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials.

Xue C, Zhou C, Dai B, Yu S, Xu C, Mao Z Oncotarget. 2015; 6(40):42515-29.

PMID: 26636542 PMC: 4767449. DOI: 10.18632/oncotarget.6452.

A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease.

Woon C, Bielinski-Bradbury A, OReilly K, Robinson P BMC Nephrol. 2015; 16:140.

PMID: 26275819 PMC: 4536696. DOI: 10.1186/s12882-015-0114-5.

References

van Dijk M, Peters D, Breuning M, Chang P . The angiotensin-converting enzyme genotype and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1999; 10(9):1916-20. DOI: 10.1681/ASN.V1091916. View

Bae K, Grantham J . Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2010; 6(2):96-106. DOI: 10.1038/nrneph.2009.214. View

Ecder T, Chapman A, Brosnahan G, Edelstein C, Johnson A, Schrier R . Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000; 35(3):427-32. DOI: 10.1016/s0272-6386(00)70195-8. View

Seeman T, Dusek J, Vondrichova H, Kyncl M, John U, Misselwitz J . Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit. 2003; 8(3):107-10. DOI: 10.1097/01.mbp.0000085762.28312.4a. View

KLAHR S, Breyer J, Beck G, Dennis V, HARTMAN J, Roth D . Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995; 5(12):2037-47. DOI: 10.1681/ASN.V5122037. View

Bennett W . Autosomal dominant polycystic kidney disease: 2009 update for internists. Korean J Intern Med. 2009; 24(3):165-8. PMC: 2732773. DOI: 10.3904/kjim.2009.24.3.165. View

Chapman A . Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008; 3(4):1197-204. DOI: 10.2215/CJN.00060108. View

Woo D . Apoptosis and loss of renal tissue in polycystic kidney diseases. N Engl J Med. 1995; 333(1):18-25. DOI: 10.1056/NEJM199507063330104. View

Hateboer N, v Dijk M, Bogdanova N, Coto E, Saggar-Malik A, San Millan J . Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999; 353(9147):103-7. DOI: 10.1016/s0140-6736(98)03495-3. View

10.

Schrier R, McFann K, Johnson A . Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003; 63(2):678-85. DOI: 10.1046/j.1523-1755.2003.00776.x. View

11.

Serra A, Poster D, Kistler A, Krauer F, Raina S, Young J . Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363(9):820-9. DOI: 10.1056/NEJMoa0907419. View

12.

Qian Q, Harris P, Torres V . Treatment prospects for autosomal-dominant polycystic kidney disease. Kidney Int. 2001; 59(6):2005-22. DOI: 10.1046/j.1523-1755.2001.00716.x. View

13.

Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C . Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363(9):830-40. DOI: 10.1056/NEJMoa1003491. View

14.

Ecder T, Edelstein C, Chapman A, Johnson A, Tison L, Gill E . Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 1999; 14(5):1113-6. DOI: 10.1093/ndt/14.5.1113. View

15.

Remuzzi G, Perico N, Macia M, Ruggenenti P . The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005; (99):S57-65. DOI: 10.1111/j.1523-1755.2005.09911.x. View

16.

Masoumi A, Reed-Gitomer B, Kelleher C, Bekheirnia M, Schrier R . Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag. 2008; 4(2):393-407. PMC: 2504069. DOI: 10.2147/tcrm.s1617. View

17.

Ulusoy S, Ozkan G, Orem C, Kaynar K, Kosucu P, Kiris A . A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. Ren Fail. 2010; 32(8):913-7. DOI: 10.3109/0886022X.2010.502277. View

18.

Fick-Brosnahan G, Belz M, McFann K, Johnson A, Schrier R . Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis. 2002; 39(6):1127-34. DOI: 10.1053/ajkd.2002.33379. View

19.

Poster D, Kistler A, Krauer F, Blumenfeld J, Rennert H, Weishaupt D . Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series. Am J Kidney Dis. 2009; 54(3):450-8. DOI: 10.1053/j.ajkd.2009.03.020. View

20.

Wuthrich R, Serra A . Mammalian target of rapamycin and autosomal dominant polycystic kidney disease. Transplant Proc. 2009; 41(6 Suppl):S18-20. DOI: 10.1016/j.transproceed.2009.06.097. View